Biogen Gross Profit 2010-2022 | BIIB

Biogen annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Biogen gross profit for the quarter ending June 30, 2022 was $2.105B, a 9.08% decline year-over-year.
  • Biogen gross profit for the twelve months ending June 30, 2022 was $8.224B, a 16.26% decline year-over-year.
  • Biogen annual gross profit for 2021 was $8.872B, a 23.78% decline from 2020.
  • Biogen annual gross profit for 2020 was $11.639B, a 6.3% decline from 2019.
  • Biogen annual gross profit for 2019 was $12.423B, a 6.75% increase from 2018.
Biogen Annual Gross Profit
(Millions of US $)
2021 $8,872
2020 $11,639
2019 $12,423
2018 $11,637
2017 $10,644
2016 $9,970
2015 $9,523
2014 $8,532
2013 $6,075
2012 $4,971
2011 $4,582
2010 $4,316
2009 $3,995
Biogen Quarterly Gross Profit
(Millions of US $)
2022-06-30 $2,105
2022-03-31 $1,778
2021-12-31 $2,074
2021-09-30 $2,267
2021-06-30 $2,315
2021-03-31 $2,216
2020-12-31 $2,362
2020-09-30 $2,927
2020-06-30 $3,271
2020-03-31 $3,080
2019-12-31 $3,224
2019-09-30 $3,170
2019-06-30 $3,140
2019-03-31 $2,888
2018-12-31 $3,038
2018-09-30 $2,978
2018-06-30 $2,936
2018-03-31 $2,685
2017-12-31 $2,798
2017-09-30 $2,708
2017-06-30 $2,712
2017-03-31 $2,426
2016-12-31 $2,494
2016-09-30 $2,539
2016-06-30 $2,524
2016-03-31 $2,414
2015-12-31 $2,507
2015-09-30 $2,468
2015-06-30 $2,306
2015-03-31 $2,243
2014-12-31 $2,343
2014-09-30 $2,209
2014-06-30 $2,130
2014-03-31 $1,851
2013-12-31 $1,707
2013-09-30 $1,593
2013-06-30 $1,493
2013-03-31 $1,281
2012-12-31 $1,284
2012-09-30 $1,246
2012-06-30 $1,282
2012-03-31 $1,159
2011-12-31 $1,187
2011-09-30 $1,186
2011-06-30 $1,108
2011-03-31 $1,100
2010-12-31 $1,119
2010-09-30 $1,080
2010-06-30 $1,106
2010-03-31 $1,012
2009-12-31 $1,027
2009-09-30 $1,027
2009-06-30 $1,003
2009-03-31 $938
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $32.069B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.361B 9.79
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.336B 18.98
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.449B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Myovant Sciences (MYOV) United Kingdom $1.774B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.82
Zymeworks (ZYME) Canada $0.430B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.118B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00